Taking a new approach to tackle neurodegenerative diseases
Drug Discovery World
OCTOBER 4, 2022
William Erhardt , President, Head of Development & Operations of biotech Oligomerix, tells Lu Rahman about the company’s differentiated approach to developing disease-modifying therapeutics for neurodegenerative diseases. . With its recent award of $3.35 Overcoming sector challenges . million in 2022 to 12.7 million by 2050.” .
52 
Let's personalize your content